NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of “Moderate Buy” from Analysts

NeuroPace, Inc. (NASDAQ:NPCE) has been given an average recommendation of “Moderate Buy” by the six research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $14.60.

Several brokerages recently weighed in on NPCE. Cantor Fitzgerald restated an “overweight” rating and issued a $18.00 price objective on shares of NeuroPace in a report on Wednesday, August 14th. Wells Fargo & Company lowered their target price on shares of NeuroPace from $15.00 to $13.00 and set an “overweight” rating for the company in a research note on Wednesday, November 13th.

Insider Buying and Selling at NeuroPace

In other NeuroPace news, major shareholder Ltd. Kck sold 4,910 shares of the stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $6.66, for a total transaction of $32,700.60. Following the completion of the transaction, the insider now owns 5,540,104 shares in the company, valued at approximately $36,897,092.64. This represents a 0.09 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders have sold 257,590 shares of company stock valued at $1,437,916. 22.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Rhumbline Advisers bought a new stake in NeuroPace during the 2nd quarter worth about $111,000. Financial Advocates Investment Management raised its holdings in NeuroPace by 50.0% during the second quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock worth $113,000 after acquiring an additional 5,000 shares in the last quarter. Barclays PLC boosted its position in NeuroPace by 346.0% during the third quarter. Barclays PLC now owns 20,633 shares of the company’s stock valued at $144,000 after purchasing an additional 16,007 shares during the last quarter. XTX Topco Ltd grew its stake in NeuroPace by 56.1% in the second quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock valued at $182,000 after purchasing an additional 8,643 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in shares of NeuroPace during the 2nd quarter worth approximately $257,000. 78.83% of the stock is owned by institutional investors and hedge funds.

NeuroPace Stock Performance

NPCE stock opened at $9.70 on Monday. The company has a 50 day moving average price of $7.13 and a 200 day moving average price of $7.24. NeuroPace has a fifty-two week low of $5.45 and a fifty-two week high of $18.15. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77. The stock has a market capitalization of $289.53 million, a PE ratio of -9.70 and a beta of 1.79.

NeuroPace (NASDAQ:NPCE) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.07. The business had revenue of $21.06 million for the quarter, compared to analyst estimates of $19.33 million. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. During the same quarter in the prior year, the firm posted ($0.28) earnings per share. Analysts forecast that NeuroPace will post -1 EPS for the current year.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.